The Ministry of Health, Labour and Welfare announced on November 13, 2026, that it has compiled and published evaluation results concerning the efforts of companies that manufacture and sell generic drugs to ensure stable supply, as part of the fiscal 2026 drug pricing revision ^[1].

According to the ministry, this evaluation was prompted by supply disruptions that arose following quality-related misconduct at generic drug companies ^[1]. The evaluation reflects discussions held at a study panel examining the industrial structure needed to achieve stable supply of generic medicines ^[1]. The ministry stated it plans to continue publishing such evaluation results from fiscal 2026 onward, and this release marks the first such disclosure under that plan ^[1].

The ministry said it will continue to pursue necessary measures to ensure that generic medicines remain stably supplied ^[1]. The full details of the evaluation results are contained in a press release document attached to the notice, which requires Adobe Reader software to view ^[1].

The ministry's notice does not specify which companies were evaluated, what criteria were used, or how the results might affect the availability of specific medicines, so readers seeking those details should consult the official press release document directly ^[1]. The notice also does not state whether or how this evaluation will directly affect drug prices or availability at pharmacies, beyond the ministry's general commitment to stable supply ^[1].

Source credit 出典：「後発医薬品を製造販売する企業の安定供給の取組に関する評価結果を公表します」（厚生労働省）（https://www.mhlw.go.jp/stf/newpage_77371.html）、PDL1.0（https://www.digital.go.jp/resources/open_data/public_data_license_v1.0）を加工してJapan News (j.apan.news)が作成 This article is Japan News's own English summary of the Japanese original. It has been translated and edited by Japan News; it is not an official translation, and the Ministry of Health, Labour and Welfare did not write or review it.